Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
I. Chernokhaeva (St.-Petersburg, Russian Federation), E. Ershova (St.-Petersburg, Russian Federation), M. Pavlova (St.-Petersburg, Russian Federation), A. Starshinova (St.-Petersburg, Russian Federation), N. Sapozhnikova (St.-Petersburg, Russian Federation). Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.. 4740

Member's Comments

No comment yet.

Related content which might interest you: Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Evaluation of the multidrug resistant TB in children with HIV infection Source: Eur Respir J 2004; 24: Suppl. 48, 439s Year: 2004 Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019 Year: 2020 Experience of isofon use for therapy and chemoprophylaxis of tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 486s Year: 2004 Multidrug-resistant TB in children with HIV infection Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019 A new era for treatment of drug-resistant tuberculosis Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018 Year: 2018 Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Application of therapeutic pneumoperitoneum for multi-drug resistant cavitary TB in HIV – infected patients Source: Eur Respir J 2004; 24: Suppl. 48, 650s Year: 2004 Treatment of latent infection with Mycobacterium tuberculosis: update 2010 Source: Eur Respir J 2011; 37: 690-711 Year: 2011 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Clinical management of tuberculosis and HIV-1 co-infection Source: Eur Respir J 2010; 36: 1460-1481 Year: 2010 Latent tuberculosis infection in a drug treatment centre Source: Eur Respir J 2002; 20: Suppl. 38, 366s Year: 2002 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 HIV and multidrug-resistant tuberculosis: overlapping epidemics Source: Eur Respir J 2014; 44: 251-254 Year: 2014 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015